Subjects: Medicine, Pharmacy >> Clinical Medicine submitted time 2022-12-23 Cooperative journals: 《中国全科医学》
Abstract：
Background Multiple myeloma is a common hematologic tumor. With the emergence of a variety of new drugs, the survival rate of patients has increased, but how to achieve deeper and faster remission of patients and reduce recurrence needs further discussion. Objective To investigate the efficacy and safety of daratumumab in the treatment of multiple myeloma. Methods The clinical data of 73 patients with multiple myeloma (70 patients with multiple myeloma and 3 patients with multiple myeloma complicated with light amyloidosis) who received daratumumab in Sichuan People's Hospital from January 2020 to July 2022 were retrospectively analyzed. Results All patients were treated with daratumumab based regimen (including DVd, DKd, Dd, etc.), and 55 patients could be evaluated for efficacy. Among them, 41 patients (56.1%) with mSMART score were at high risk. Among chemotherapy regimens, 31 patients received DVd regimen ( daratumumab + bortezomib + dexamethasone), 13 patients received Dd regimen ( daratumumab + dexamethasone), and 11 patients received DRd regimen ( daratumumab+ lenalidomide + dexamethasone). 5 cases were treated with DKd ( daratumumab + carfilzomib + dexamethasone) , 5 cases were treated with DPd ( darettuzumab + pomalidomide + dexamethasone) , and 8 cases were treated with other regimen. The overall response rate (ORR) was 72.7%[complete response rate (CR) was 30.9%], the median follow-up time was 6.5 months (0.5-26.5 months), and the progression-free survival (PFS) time was 6 (0.5-26.5) months after one course of the darettuzumab based regimen. Median overall survival (OS) was 16(3 to 103) months. Overall response rate (ORR) was 90.0%[complete response rate (CR) was 35.0%] in first-line darettuzumab patients and 58.3%[complete response rate (CR) was 25%] in relapsed refractory patients. Thirty-one patients (42.5%) had renal impairment at initial diagnosis, 20 patients (83.3%) had improved renal function after the administration of darettuzumab, and 7 patients (29.1%) had completely recovered renal function. The main adverse reactions were myelosuppression, infusion - related adverse reactions, and infection. Conclusion The daratumumab based regimen has good efficacy and safety in the treatment of multiple myeloma.
Hits
Hits
Downloads
Comment